伏环孢素疗效与安全性概览更新:狼疮肾炎临床试验的整合分析
该整合分析汇总AURA-LV(II期)与AURORA 1(III期)两项随机、安慰剂对照、双盲试验,评估伏环孢素23.7 mg每日两次联合吗替麦考酚酯(MMF)及口服糖皮质激素治疗狼疮肾炎的疗效与安全性;共534例患者(伏环孢素组268例,对照组266例),伏环孢素组一年完全肾脏缓解率显著高于对照组(43.7% vs 23.3%;OR 2.76;95%CI 1.88, 4.05;P<0.0001),未发现新的或非预期安全信号。
要点
- 伏环孢素组一年完全肾脏缓解率为43.7%,对照组为23.3%(OR 2.76;95%CI 1.88, 4.05;P<0.0001)。
- 不良事件发生率伏环孢素组91.4%、对照组87.2%,多为轻至中度。
- 最常见不良事件为感染及侵染类(62.2% vs 54.9%)和胃肠道疾病(45.3% vs 35.3%安慰剂)。
核心结论
- 该整合分析显示伏环孢素在受研究的多种族和民族人群中治疗狼疮肾炎具有疗效和安全性。
研究设计与样本
- 整合分析汇总AURA-LV(II期)与AURORA 1(III期)两项随机、安慰剂对照、双盲试验,设计及终点相似,比较伏环孢素联合MMF及口服糖皮质激素与对照联合MMF及口服糖皮质激素治疗狼疮肾炎。
- 共纳入534例患者(伏环孢素组268例;对照组266例)。
- 主要疗效结局为约一年时的完全肾脏缓解(CRR),采用AURA-LV第48周数据和AURORA 1第52周数据。
- 安全性在整个试验期间评估。
主要发现
- 伏环孢素组一年时达到CRR的患者显著多于对照组(43.7% vs 23.3%;OR 2.76;95%CI 1.88, 4.05;P<0.0001)。
- 不良事件发生率两组相似(伏环孢素组91.4%;对照组87.2%)。
- 大多数不良事件为轻至中度;最常见不良事件为感染及侵染类(伏环孢素组62.2%;对照组54.9%)和胃肠道疾病(伏环孢素组45.3%;安慰剂组35.3%)。
- 未检测到新的或非预期安全信号。
关键数值与推荐
- 伏环孢素用法为23.7 mg每日两次,联合MMF及口服糖皮质激素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations. METHODS: Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA-LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo-controlled, double-blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA-LV and Week 52 from AURORA 1). Safety was assessed throughout the trials. RESULTS: Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 P < 0.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected. CONCLUSIONS: This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.
引用
- Arriens C, Teng YKO, Ginzler EM, et al. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care Res (Hoboken). 2023. PMID: 36039949. doi:10.1002/acr.25007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。